Patient characteristics | Control group (n=21) | Training group (n=22) |
---|---|---|

Anthropometric data | ||

Sex (F/M) | 17/4 | 17/5 |

Age, years old; mean (SD) | 44 (9) | 40 (11) |

BMI, kg/m^{2}; mean (SD) | 26.4 (4.3) | 26.5 (4.2) |

Medication | ||

Budesonide dosage, µg/day; mean (SD) | 804 (370) | 909 (594) |

Long-acting β_{2} agonists, µg/day; mean (SD) | 34.5 (32.1) | 26.7 (17.7) |

Onset of asthma in childhood, n (%) | 12 (57) | 17 (77) |

IgE, IU/mL; median (25th–75th) | 289.0 (57–877) | 451.5 (151–1183) |

Atopy, n (%) | 15 (71.4) | 20 (91.0) |

BHR, PC_{20}, mg/mL; median (25th–75th) | 0.5 (0.3–1.7) | 0.3 (0.2–0.5) |

Eosinophils, %; median (25th–75th) | 6.1 (9) | 10.1 (12) |

FeNO, ppb; median (25th–75th) | 26.7 (22.5–38.9) | 32.0 (21.1–44.8) |

ACQ-7, score; mean (SD) | 1.6 (0.9) | 1.4 (1.2) |

Exacerbations in the last 12 months; no. events/patients | 1.9 | 1.2 |

AQLQ, total score; mean (SD) | 4.2 (1.1) | 4.6 (1.4) |

Aerobic capacity, VO_{2max}, mL/kg/min; mean (SD) | 25.5 (5.9) | 27.0 (4.3) |

Pulmonary function | ||

FEV_{1}, %; mean (SD) | 66.3 (19.0) | 69.0 (21.0) |

FEV_{1}/FVC, %; mean (SD) | 72.2 (10.0) | 73.0 (10.5) |

Data are presented as mean±SD unless otherwise stated.

ACQ-7, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BHR, bronchial hyperresponsiveness; BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV

_{1}, forced expiratory volume in 1 s; FVC, forced vital capacity; IgE, immunoglobulin E; PC_{20}, provocation concentration of histamine causing a 20% decrease in FEV_{1}; ppb, parts per billion; VO_{2}max, maximal oxygen consumption.